Registered since
-Turnover in CHF
-Capital in CHF
-Employees
-Active brands
-Reports for Altamira Therapeutics AG
There is no information available because this company has been deleted.
Credit rating information
Evaluation of credit rating with traffic light as risk indicator and other helpful data about the company.Find out more
Economic information
Comprehensive information about the economic situation of a company.Find out more
Payment collection information
Overview of current and past debt enforcement proceedings.Find out more
Shareholder Information
Find out which national and international companies the stock corporation you are interested in also holds shares in.Find out more
Company dossier as PDF
Contact information, changes in the company, turnover and employee figures, management, ownership, shareholding structure and other company data.Retrieve company dossier
Commercial register information
Entry in the commercial register
10.12.2019
Deletion from the commercial register
05.07.2024
Legal form
Company limited by shares (AG)
Legal headquarters of the company
Basel
Commercial Registry Office
BS
Commercial register number
CH-170.3.044.145-8
UID/VAT
CHE-242.224.641
Sector
Production of pharmaceutical substances
Purpose (Original language)
Entwicklung und Vermarktung von Medikamenten, Medizinprodukten und medizinischen Dienstleistungen aller Art; vollständige Zweckumschreibung gemäss Statuten.
Other company names
Past and translated company names
- Altamira Therapeutics Ltd
- Altamira Therapeutics SA
- Zilentin AG
- Zilentin Ltd
- Zilentin SA
Branches (0)
Ownership structure
Holdings
Newest SOGC notifications: Altamira Therapeutics AG
The latest updates from the Swiss Official Gazette of Commerce (SOGC) are available in the original language of the source commercial register office only. View all notifications
Publication number: HR03-1006077107, Commercial Registry Office Basel-Stadt, (270)
Altamira Therapeutics AG, in Basel, CHE-242.224.641, Aktiengesellschaft (SHAB Nr. 237 vom 06.12.2023, Publ. 1005902586).
Aktiven und Passiven (Fremdkapital) gehen infolge Fusion auf die Auris Medical AG (neu:
Altamira Therapeutics AG), in Basel (CHE-455.709.593), über. Die Gesellschaft wird gelöscht.